Drug Profile


Alternative Names: SYL-040012

Latest Information Update: 11 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sylentis
  • Class Antiglaucomas; Small interfering RNA
  • Mechanism of Action Beta 2 adrenergic receptor antagonists; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glaucoma; Ocular hypertension

Most Recent Events

  • 11 Sep 2018 Bamosiran is still in phase II trials for Glaucoma and Ocular hypertension (Sylentis pipeline, September 2018)
  • 02 Oct 2015 Interim efficacy and adverse events data from a phase IIb SYLTAG trial in Ocular hypertension released by Sylentis
  • 17 Aug 2015 Phase-II development is ongoing for Glaucoma and Ocular hypertension in Europe and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top